The synthesis and isolation of 12 alpha-aryl, beta, beta'-disilyl-substituted vinyl cations 1b-l, 7, and 8 with the tetrakis(pentafluorophenyl)borate counteranion is reported. The vinyl cations are characterized by NMR spectroscopy and are identified by their specific NMR chemical shifts (delta13C(C(+)) = 178.1-194.5; delta13C (Cbeta) = 83.3-89.9; delta13C (Cipso)) = 113.6-115.2; delta (29)Si = 25.0-12.0), supported by density functional calculations at the B3LYP/6-311G(2d,p)//B3LYP/6-31G(d) level. All cations are found to be stable at room temperature in solution and in the solid state. The NMR chemical shifts as well as J-coupling data indicate for vinyl cations, 1b-l, 7, and 8, the occurrence of substantial stabilization through pi-resonance via the aryl substituents and through sigma-delocalization via the beta-silyl groups. For vinyl cation 8, the free enthalpy of stabilization via pi-resonance by the alpha-ferrocenyl substituent is determined by temperature-dependent (29)Si NMR spectroscopy to be DeltaG++ = (48.9 +/- 4.2) kJ mol(-1). A Hammett-type analysis, which relates the (1)J(SiC(beta)) coupling constant and the low-field shift of the (29)Si NMR signal upon ionization, Deltadelta (29)Si, with the electron-donating ability of the aryl group, indicates an inverse relation between the extent of Si-C hyperconjugation and pi-donation. The computed structures (at B3LYP/6-31G(d)) of the vinyl cations 1a-l, 7, and 8 reveal the consequences of Si-C hyperconjugation and of pi-resonance interactions with the aryl groups. The structures, however, fail to express the interplay between sigma-delocalization and pi-conjugation in that the calculated Si-C bond lengths and the C+-C(ipso) bond lengths do not vary as a function of the substituent.
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors, playing a pivotal role in energy homeostasis. Activators of the PPARalpha subtype are in widespread use for the treatment of hyperlipidemia, while activators of the PPARgamma subtype are in clinical use for the treatment of type-2 diabetes. Since both of these diseases are frequently associated, the combined treatment with one drug simultaneously activating PPARalpha and PPARgamma seems worthwhile. Starting with pirinixic acid, which is a moderately active dual PPARalpha/gamma agonist, we improved potency at the human PPARalpha and PPARgamma by substituting the alpha-position with an aliphatic chain. The maximal effect was achieved at a chain length of four and six carbons, respectively, leading to an activity induction by a factor of 36 for PPARalpha and 18 for PPARgamma, respectively.
A series of beta,beta-disilyl-substituted vinyl cations were prepared by intramolecular addition of transient silylium ions to C[triple bond]C triple bonds. The vinyl cations were isolated from hydrocarbon solutions as tetrakis(pentafluorophenyl) borates at room temperature. The substituents directly attached to the positively charged carbon atom were varied from tert-butyl- to trialkylsilyl- to trialkylgermyl groups. The cations were identified by their characteristic (13)C and (29)Si NMR data. The NMR investigations revealed for beta,beta-disilyl-alpha-germyl- and trisilyl-substituted vinyl cations a highly dynamic structure in which both vinylic carbon atoms undergo an intramolecular exchange process which is fast on the NMR time scale at room temperature. NMR studies using a doubly (13)C-labeled vinyl cation suggest as mechanism for this exchange process a rotation of the dicarbyne C[triple bond]C(2-) unit within the triangle defined by the three cationic silyl fragments. Therefore the dynamic structure indicated for trisilyl- or disilylgermyl-substituted vinyl cations parallels the situation found for the parent vinyl cation, the protonated acetylene.
We report the combination of chemical cross-linking and high-resolution mass spectrometry for analyzing conformational changes in target proteins that are induced by drug binding. With this approach conformational changes in the peroxisome proliferator-activated receptor alpha (PPARalpha) upon binding of low-molecular weight compounds were readily detected, proving that the strategy provides a basis to efficiently characterize target protein-drug interactions.
Pirinixic acid is known for its peroxisome proliferator-activated receptor (PPAR) agonistic action. In a recent publication, we have shown that aliphatic alpha-substitution of pirinixic acid enhances both PPARalpha and PPARgamma agonism. The goal of this study was to evaluate, whether the PPAR agonism of pirinixic acid may be also maintained in quinoline-based derivatives. The present study revealed that the mere substitution of the dimethyl aniline moiety of pirinixic acid by quinoline leads to a total loss of PPARalpha/gamma agonism, whereas concomitant alpha-substitution with n-butyl or n-hexyl groups restores and even enforces PPAR activation, leading to potent dual PPARalpha/gamma agonists. In the following we report the synthesis of quinoline-based derivatives of pirinixic acid, which in a Gal4-based luciferase-reporter gene assay proved to be potent dual PPARalpha/gamma agonists. Molecular docking of compound 4 with FlexX suggests a binding mode resembling to that of tesaglitazar.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.